Porownywarka

PT-141 vs Melanotan II side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

PT-141Melanotan II

Udostępnij porównanie peptydów

Wlasciwosc	PT-141	Melanotan II
Kategoria	Zdrowie seksualne	Zdrowie seksualne
Znany tez jako	Bremelanotide, Vyleesi	MT-II, MT2, Melanotan 2
Zatwierdzony przez FDA	Tak	Nie
Status kliniczny	FDA Approved for HSDD in premenopausal women Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Not approved; research reportedly discontinued due to side effects. Source also lists FDA Category 2 restricted status tied to melanoma risk and other safety concerns. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Sexual desire, erectile dysfunction, low libido	Tanning, libido enhancement, erectile function
Jak dziala	PT-141, also known as bremelanotide, is described as a melanocortin peptide with central nervous system activity. The supplied source points to melanocortin receptor activation in hypothalamic pathways, mainly MC4R with some MC3R involvement, as the proposed route for effects on sexual desire and arousal. The source contrasts this with PDE5 inhibitors by noting that PT-141 is not primarily framed as a genital blood-flow drug. Reported nausea and temporary blood-pressure or heart-rate changes are also linked by the source to melanocortin receptor activity.	Melanotan II is reported as a broad melanocortin receptor agonist rather than a receptor-selective compound. The source names MC1, MC3, MC4, and MC5 as targets. MC1 signaling in melanocytes is tied to melanin production, while MC4 signaling in the central nervous system is linked to sexual arousal and desire pathways. The broad receptor profile is also presented as a reason for a wider adverse-effect profile.
Typowe dawkowanie	1.75 mg as needed · As needed, at least 45 min before activity	250-500 mcg daily (loading), then 500-1,000 mcg weekly (maintenance) · Daily during loading (1-2 weeks), then weekly maintenance · Loading 1-2 weeks, then maintenance · Subcutaneous injection
Dawkowanie z badań	1.75 mg · As needed, at least 45 min before activity · Subcutaneous injection; autoinjector available	250-500 mcg initially · Loading phase 2-3 weeks, then maintenance · Subcutaneous injection
Typowy czas trwania	As needed, at least 45 min before activity	Loading phase 2-3 weeks, then maintenance
Podanie	Subcutaneous injection; autoinjector form reported	Subcutaneous injection
Timing	1-2 hours before sexual activity With or without food	Evening or before sun exposure With or without food
Poziom dowodów	Zatwierdzone przez FDA	Badawcze
Mozliwe skutki uboczne	Nausea (Source reports nausea around 40% and identifies it as the most common adverse effect.) Facial flushing (Source reports facial flushing around 20%.) Injection-site reactions (Reported in the source without a quantified severity note.) +5 więcej Headache (Reported in the source without a quantified severity note.) Transient blood pressure increase (Source notes temporary blood-pressure elevation as a safety consideration.) Skin hyperpigmentation with frequent use (Reported in the source in connection with frequent use.) Vomiting (Reported in the source without a quantified severity note.) Fatigue (Reported in the source without a quantified severity note.)	Nausea (Reported as common, especially initially.) Facial flushing Fatigue +6 więcej Spontaneous penile erections Darkening of skin and moles (Source highlights mole changes and pigmentation concerns.) Priapism (Source flags this as an emergency-risk adverse event.) Association with melanoma risk (Source links restricted status and dermatology cautions to melanoma risk concerns.) Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Legal restriction caution (Source reports illegality in the US, UK, and Australia; this regulatory claim needs admin review.)
Podsumowanie researchu	The source presents PT-141/bremelanotide as a peptide with comparatively strong clinical evidence because it completed an FDA program for a defined indication. It summarizes two phase 3 RECONNECT studies involving 1,267 premenopausal women with HSDD who received as-needed 1.75 mg subcutaneous bremelanotide or placebo. Reported outcomes included statistically significant improvements in sexual desire and distress related to low desire, while the source characterizes the absolute benefit as modest. It also notes nausea in about 40% of women, discontinuations related to nausea, and a cap of 8 doses per month. Evidence for male libido or erectile dysfunction use is described as off-label and less developed than the approved HSDD indication.	The supplied research summary describes narrow older human evidence for erectile-function outcomes. In men with organic erectile dysfunction, the source reports subjectively described erections after 12 of 19 Melanotan II injections compared with 1 of 21 placebo doses, plus longer rigidity periods and greater sexual interest; nausea and yawning were frequent. The source connects this effect profile to later bremelanotide development. For tanning, the same source emphasizes lack of large safety trials and dermatology concerns including changing moles, melanoma reports, uneven or lasting pigmentation changes, nausea, and risks from unregulated injected material.
Referencje	PubMed PubMed +2 więcej ClinicalTrials.gov PubMed	WikipediaMelanotan II PubMedPubMed record 11018622 +1 więcej DermNetMelanotan II
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

PT-141

Melanotan II

Kategoria

Zdrowie seksualne

Znany tez jako

Bremelanotide, Vyleesi

MT-II, MT2, Melanotan 2

Zatwierdzony przez FDA

Tak

Nie

Status kliniczny

FDA Approved for HSDD in premenopausal women

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Not approved; research reportedly discontinued due to side effects. Source also lists FDA Category 2 restricted status tied to melanoma risk and other safety concerns.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Sexual desire, erectile dysfunction, low libido

Tanning, libido enhancement, erectile function

Jak dziala

PT-141, also known as bremelanotide, is described as a melanocortin peptide with central nervous system activity. The supplied source points to melanocortin receptor activation in hypothalamic pathways, mainly MC4R with some MC3R involvement, as the proposed route for effects on sexual desire and arousal. The source contrasts this with PDE5 inhibitors by noting that PT-141 is not primarily framed as a genital blood-flow drug. Reported nausea and temporary blood-pressure or heart-rate changes are also linked by the source to melanocortin receptor activity.

Melanotan II is reported as a broad melanocortin receptor agonist rather than a receptor-selective compound. The source names MC1, MC3, MC4, and MC5 as targets. MC1 signaling in melanocytes is tied to melanin production, while MC4 signaling in the central nervous system is linked to sexual arousal and desire pathways. The broad receptor profile is also presented as a reason for a wider adverse-effect profile.

Typowe dawkowanie

1.75 mg as needed · As needed, at least 45 min before activity

250-500 mcg daily (loading), then 500-1,000 mcg weekly (maintenance) · Daily during loading (1-2 weeks), then weekly maintenance · Loading 1-2 weeks, then maintenance · Subcutaneous injection

Dawkowanie z badań

1.75 mg · As needed, at least 45 min before activity · Subcutaneous injection; autoinjector available

250-500 mcg initially · Loading phase 2-3 weeks, then maintenance · Subcutaneous injection

Typowy czas trwania

As needed, at least 45 min before activity

Loading phase 2-3 weeks, then maintenance

Podanie

Subcutaneous injection; autoinjector form reported

Subcutaneous injection

Timing

1-2 hours before sexual activity

With or without food

Evening or before sun exposure

With or without food

Poziom dowodów

Zatwierdzone przez FDA

Badawcze

Mozliwe skutki uboczne

Nausea (Source reports nausea around 40% and identifies it as the most common adverse effect.)
Facial flushing (Source reports facial flushing around 20%.)
Injection-site reactions (Reported in the source without a quantified severity note.)

+5 więcej

Headache (Reported in the source without a quantified severity note.)
Transient blood pressure increase (Source notes temporary blood-pressure elevation as a safety consideration.)
Skin hyperpigmentation with frequent use (Reported in the source in connection with frequent use.)
Vomiting (Reported in the source without a quantified severity note.)
Fatigue (Reported in the source without a quantified severity note.)

Nausea (Reported as common, especially initially.)
Facial flushing
Fatigue

+6 więcej

Spontaneous penile erections
Darkening of skin and moles (Source highlights mole changes and pigmentation concerns.)
Priapism (Source flags this as an emergency-risk adverse event.)
Association with melanoma risk (Source links restricted status and dermatology cautions to melanoma risk concerns.)
Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Legal restriction caution (Source reports illegality in the US, UK, and Australia; this regulatory claim needs admin review.)

Podsumowanie researchu

The source presents PT-141/bremelanotide as a peptide with comparatively strong clinical evidence because it completed an FDA program for a defined indication. It summarizes two phase 3 RECONNECT studies involving 1,267 premenopausal women with HSDD who received as-needed 1.75 mg subcutaneous bremelanotide or placebo. Reported outcomes included statistically significant improvements in sexual desire and distress related to low desire, while the source characterizes the absolute benefit as modest. It also notes nausea in about 40% of women, discontinuations related to nausea, and a cap of 8 doses per month. Evidence for male libido or erectile dysfunction use is described as off-label and less developed than the approved HSDD indication.

The supplied research summary describes narrow older human evidence for erectile-function outcomes. In men with organic erectile dysfunction, the source reports subjectively described erections after 12 of 19 Melanotan II injections compared with 1 of 21 placebo doses, plus longer rigidity periods and greater sexual interest; nausea and yawning were frequent. The source connects this effect profile to later bremelanotide development. For tanning, the same source emphasizes lack of large safety trials and dermatology concerns including changing moles, melanoma reports, uneven or lasting pigmentation changes, nausea, and risks from unregulated injected material.

Referencje

PubMed PubMed

+2 więcej

ClinicalTrials.gov PubMed

WikipediaMelanotan II PubMedPubMed record 11018622

+1 więcej

DermNetMelanotan II

Pełny profil

Zobacz szczegóły